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Long-chain x-3 polyunsaturated fatty acids (PUFAs) may have antineoplastic properties in the colon. The authors
examined the association between intakes of different PUFAs and distal large bowel cancer in a population-based
case-control study of 1,503 whites (716 cases; 787 controls) and 369 African Americans (213 cases; 156 controls)
in North Carolina (2001–2006). Unconditional logistic regression was used to estimate odds ratios and 95%
confidence intervals for distal large bowel cancer risk in relation to quartiles of PUFA intake. Increased consump-
tion of long-chain x-3 PUFAs was associated with reduced risk of distal large bowel cancer in whites (multivariable
odds ratios ¼ 0.88 (95% confidence interval (CI): 0.63, 1.22), 0.69 (95% CI: 0.49, 0.98), and 0.49 (95% CI: 0.34,
0.71) for second, third, and highest vs. lowest quartile) (Ptrend < 0.01). Intake of individual eicosapentaenoic acids
and docosahexaenoic acids was inversely related to distal large bowel cancer risk, whereas the ratio of x-6 to long-
chain x-3 PUFAs was associated with increased risk of distal large bowel cancer in whites, but not among African
Americans (Pinteraction < 0.05). Study results support the hypothesis that long-chain x-3 PUFAs have beneficial
effects in colorectal carcinogenesis. Whether or not the possible benefit of long-chain x-3 PUFAs varies by race
warrants further evaluation.
colorectal neoplasms; fatty acids, omega-3; fatty acids, unsaturated; intestine, large
Abbreviations: CI, confidence interval; COX, cyclooxygenase; NSAID, nonsteroidal antiinflammatory drug; OR, odds ratio;
PUFA, polyunsaturated fatty acid.
Experimental and clinical data have shown that x-3
polyunsaturated fatty acids (PUFAs) have beneficial effects
in colorectal carcinogenesis, including reduced tumor growth
(1, 2), suppression of angiogenesis (3), and inhibition of me-
tastasis (4, 5). In particular, long-chain, marine x-3 PUFAs,
such as eicosapentaenoic acid and docosahexaenoic acid, are
effective competitors against arachidonic acid for the compo-
sition of membrane phospholipids and cyclooxygenase
(COX) enzyme, inhibiting production of proinflammatory
and tumorigenic prostaglandins and leukotrienes (6, 7). Sup-
plementation with fish oil containing eicosapentaenoic acid
and docosahexaenoic acid has been shown to decrease levels
of inflammatory mediators and to reduce dependency on non-
steroidal antiinflammatory drugs (NSAIDs) and other pain
medications in patients with arthritis (8). In a small clinical
trial, fish oil supplementation significantly reduced cell pro-
liferation on rectal mucosa in patients with colorectal adeno-
mas compared with placebo after 12 weeks (9).
In contrast, epidemiologic evidence has been inconsis-
tent. Only 1 of 9 prospective studies included in an earlier
systematic review reported an inverse association between
x-3 PUFA intake and colorectal cancer (10). More recently,
intake of x-3 fatty acids has been associated with lower risk
of colorectal cancer in both case-control (11) and prospec-
tive (12) studies. Other studies found the inverse association
only among specific subgroups (13–15). We therefore ex-
amined the association between intakes of different PUFAs
and distal large bowel cancer in a population-based case-
control study of whites and African Americans. We also
evaluated race, NSAID use, obesity, and tumor location as
potential effect measure modifiers of the relation between
intake of polyunsaturated fatty acids and distal large bowel
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cancer. Race and tumor location were chosen on the basis of
previous findings suggesting etiologic heterogeneity of co-
lorectal cancer by race (16) and tumor location (17), and
NSAID use and obesity were chosen a priori because of
their shared implications in COX-associated inflammation
pathways (18, 19).
MATERIALS AND METHODS
North Carolina Colon Cancer Study II
The North Carolina Colon Cancer Study II is a population-
based case-control study in 33 counties in the central and
eastern parts of North Carolina. To be eligible for the study,
subjects had to be residents of the selected counties, aged
between 40 and 80 years, African American or white race,
and able to complete an interview in English. Subjects had to
have a North Carolina driver’s license or identification card.
The cases were patients with a first diagnosis of invasive
adenocarcinoma in the sigmoid, rectosigmoid, or rectum di-
agnosed between October 1, 2001, and May 31, 2006. A total
of 1,831 eligible cases were identified through the rapid
ascertainment system of the North Carolina Central Cancer
Registry. The procedure for case ascertainment and its
effectiveness has been described (20). Of the cases identified,
57 (3%) were excluded because of physician refusal, and 357
(20%) were found to be ineligible. Of the remaining 1,417
eligible cases, 118 (8%) could not be contacted, 242 (17%)
refused to participate, and 1,057 (75%) completed an in-
person interview.
Controls were randomly selected from records of the
North Carolina Division of Motor Vehicles, on the basis
of sampling probabilities within blocks defined by 5-year
age group, sex, and race, by use of randomized recruitment
(21). A total of 2,345 subjects were identified as potentially
eligible controls, and 1,827 (78%) met eligibility criteria. Of
these, 325 (18%) could not be contacted, 483 (26%) refused
to participate, and 1,019 (56% of eligible controls) com-
pleted an in-person interview.
Of a total 2,076 subjects, dietary information was avail-
able for 2,044. We further excluded 172 subjects with im-
plausible energy intake: if daily energy intake was less than
500 kcal (n ¼ 4) or greater than 3,500 kcal (n ¼ 37) in
women or less than 800 kcal (n ¼ 12) or greater than
4,000 kcal (n ¼ 119) in men (22). The final data set for
analysis included 1,872 subjects (929 cases and 943 con-
trols). The study was approved by the Institutional Review
Board at the University of North Carolina School of Med-
icine, and all subjects provided written informed consent.
Data collection
All subjects were interviewed in person in their home or in
another convenient location by trained nurse interviewers
using a standard questionnaire. The questionnaire included
information regarding demographic characteristics, socio-
economic indicators (such as years of education, income
level, and occupation history), medication use, medical his-
tory, family history of cancer, smoking habits, and weight 1
year prior to diagnosis (for cases) or interview (for controls).
Subjects were also asked about the type and duration of
various activities engaged in on typical week (working)
and weekend (nonworking) days. Then the energy expendi-
ture involved in each activity was retrieved from the ‘‘Com-
pendium of Physical Activities.’’ Metabolic equivalents were
calculated by multiplying the number of hours spent in these
activities, the number of metabolic equivalents for the cate-
gory, and body weight (23). Current weight and height were
measured at the time of interview. Cancer stage (local,
regional, distant, or unknown), tumor location (sigmoid,
rectosigmoid, or rectum), and other diagnosis-related data
were available from the Central Cancer Registry.
Dietary assessment
Dietary information was collected by using the Diet His-
tory Questionnaire, a validated food frequency questionnaire
with 124 food items developed at the National Cancer In-
stitute (24). Subjects were asked about a common unit or
portion size for each food and the average consumption fre-
quency of the food in the past year. Information about types
of oil or other fats usually used for frying, sautéing, basting,
or marinating was also collected. Nutrient intake was calcu-
lated by using the Diet*Calc software program provided by
the National Cancer Institute (http://riskfactor.cancer.gov/
DHQ/dietcalc/) (25). Briefly, an individual’s nutrient intake
was computed by multiplying the frequency of consumption
of each food by gender-specific mean nutrient or food group
values and portion size based on national dietary intake data
from the 1994–1996 US Department of Agriculture’s Con-
tinuing Survey of Food Intake by Individuals (CSFII).
Intakes of 19 different fatty acids were estimated includ-
ing 7 PUFAs: linoleic acid (18:2), a-linolenic acid (18:3),
stearidonic acid (18:4), arachidonic acid (20:4), eicosapen-
taenoic acid (20:5), docosapentaenoic acid (22:5), and do-
cosahexaenoic acid (22:6). Total x-6 PUFA intake was
calculated as the sum of linoleic acid and arachidonic acid,
and the total x-3 PUFA intake was the sum of a-linolenic
acid, stearidonic acid, eicosapentaenoic acid, docosapenta-
enoic acid, and docosahexaenoic acid. Long-chainx-3 PUFA
intake was computed to reflect the sum of eicosapentaenoic
acid, docosapentaenoic acid, and docosahexaenoic acid.
Our nutrient analysis did not allow us to examine food
source-specific nutrient intake. In theWestern diet, however,
approximately 70% of dietary long-chain x-3 fatty acids
come from fish and other seafood, whereas cereal-based
dishes and oils are the major dietary source of short-chain
x-3 fatty acids (26). These food items are well covered by
the food frequency questionnaire used in this study.
Statistical analysis
Selected characteristics were compared between cases
and controls. Subjects were divided into 4 groups based
on the distribution of each PUFA intake among controls.
Unconditional logistic regression was used to estimate odds
ratios and 95% confidence intervals for the association be-
tween intakes of different PUFAs and distal large bowel
cancer. Linear trends across quartiles of PUFA intake were
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Table 1. Characteristics of Cases and Controls, North Carolina Colon Cancer Study II, 2001–2006
Cases (n 5 929) Controls (n 5 943)
P Value
No. % Mean (SD) No. % Mean (SD)
Age, years <0.01
40–49 119 12.8 93 9.9
50–59 249 26.8 216 22.9
60–69 287 30.9 300 31.8
70–79 274 29.5 334 35.4
Mean years 62 64
Females 441 44.2 400 42.4 0.43
African Americans 213 22.9 156 16.5 <0.01
Years of education <0.01
<12 174 19.2 109 11.8
12–15 481 53.1 460 49.8
16 251 27.7 354 38.4
Annual household income 0.04
<$15,000 157 18.4 124 14.3
$15,000–$24,999 145 17 135 15.6
$25,000–$49,999 211 24.7 212 24.5
$50,000 341 39.9 396 45.7
Smoking status 0.36
Never 340 37.6 352 38.4
Past 417 46 437 47.7
Current 148 16.4 128 14
Body mass index 1 year prior <0.01
Normal 198 22.7 271 30.2
Overweight 324 37.2 359 40
Obese 350 40.1 268 29.8
Physical activity, MET-minutes/day <0.01
<1,849 249 28.6 217 24.5
1,849–<1,962 188 21.6 222 25.1
1,962–<2,190 176 20.2 221 25
2,190 257 29.5 225 25.4
Use of NSAIDs 689 76.1 771 83.6 <0.01
HRT use in females 147 35.9 190 49.2 <0.01
Family history of colorectal cancer 120 18.4 97 14 0.03
Endoscopic screening 202 22.4 583 63.4 <0.01
Dietary intakes
Calories, kcal/day 2,180.5 (752.8) 2,056.8 (694.9) <0.01
Fat, g/day 87.3 (36.3) 82.2 (35.2) <0.01
Red meat, g/day 73.8 (52.8) 67.8 (46.5) <0.01
Fruits/vegetables, servings/day 2.6 (1.5) 2.8 (1.6) <0.01
Vitamin E, mg/day 9.7 (4.5) 9.9 (4.6) 0.29
PUFAs, g/day 20.2 (8.9) 19.3 (8.6) 0.03
x-6 PUFAs, g/day 18.1 (8.1) 17.3 (7.8) 0.03
Arachidonic acid, mg/day 120.0 (61.9) 115.0 (60.1) 0.08
x-3 PUFAs, g/day 1.9 (0.8) 1.9 (0.8) 0.03
Short-chain x-3 PUFAs, g/day 1.8 (0.8) 1.7 (0.8) <0.01
a-Linolenic acid, g/day 1.8 (0.8) 1.7 (0.8) <0.01
Long-chain x-3 PUFAs, mg/day 124.6 (112.2) 139.6 (121.6) <0.01
Eicosapentaenoic acid, mg/day 35.1 (37.7) 40.8 (41.1) <0.01
Docosahexaenoic acid, mg/day 73.2 (61.9) 81.6 (67.6) <0.01
x-6:x-3 PUFA ratio 9.5 (2.1) 9.5 (2.2) 0.96
x-6:long-chain x-3 PUFA ratio 258.3 (272.8) 223.4 (249.4) <0.01
Abbreviations: HRT, hormone replacement therapy; MET, metabolic equivalent; NSAID, nonsteroidal antiinflam-
matory drug; PUFA, polyunsaturated fatty acid.
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assessed by modeling the categorical variable as a continu-
ous variable.
All logistic regression models included age (40–44, 45–
49, 50–54, 55–59, 60–64, 65–69, 70–74, or 75–79 years),
sex, race, daily energy intake during the past year (quintiles
based on the distribution among controls), and an offset
term to adjust for sampling probability. A randomized re-
cruitment method was used for selection of cases and con-
trols to achieve oversampling of cases in certain categories
and their probability-matched controls. Because this method
systematically introduces a bias in the estimated odds ratios,
the odds ratios should be corrected by including a fixed off-
set term corresponding to the sampling categories which, in
this case, were of age, sex, race, and case-control status (21).
Table 2. Association Between Quartiles of Polyunsaturated Fatty Acid Intake and Distal Large

















<13.1 196 235 1.00 Referent 1.00 Referent
13.1–<18.1 226 235 1.14 0.84, 1.54 1.16 0.81, 1.67
18.1–<24.4 242 238 1.07 0.76, 1.49 1.14 0.74, 1.76
24.4 265 235 0.93 0.63, 1.37 0.99 0.59, 1.67
Ptrend 0.63 0.95
Total x-6 PUFAs, g/day
<11.5 196 232 1.00 Referent 1.00 Referent
11.5–<16.3 232 240 1.13 0.84, 1.53 1.09 0.76, 1.56
16.3–<22.0 242 238 1.02 0.73, 1.43 1.07 0.69, 1.65
22.0 259 233 0.88 0.59, 1.30 0.87 0.52, 1.47
Ptrend 0.42 0.61
Arachidonic acid, g/day
<0.07 154 198 1.00 Referent 1.00 Referent
0.07–<0.1 211 215 1.22 0.91, 1.65 1.17 0.82, 1.68
0.1–<0.15 297 272 1.27 0.93, 1.72 1.09 0.74, 1.59
0.15 267 258 0.93 0.66, 1.31 0.83 0.53, 1.31
Ptrend 0.67 0.36
Total x-3 PUFAs, g/day
<1.27 198 233 1.00 Referent 1.00 Referent
1.27–<1.72 218 238 1.07 0.80, 1.43 1.10 0.78, 1.55
1.72–<2.31 247 235 1.08 0.79, 1.50 1.14 0.76, 1.67




<1.16 194 230 1.00 Referent 1.00 Referent
1.16–<1.57 194 236 0.97 0.72, 1.30 0.99 0.70, 1.41
1.57–<2.14 265 241 1.20 0.87, 1.64 1.23 0.84, 1.81




<1.16 198 233 1.00 Referent 1.00 Referent
1.16–<1.57 194 237 0.95 0.71, 1.28 0.98 0.69, 1.38
1.57–<2.13 257 235 1.18 0.86, 1.62 1.20 0.81, 1.76
2.13 280 238 1.05 0.73, 1.51 1.03 0.66, 1.60
Ptrend 0.53 0.72
Table continues
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Results without the inclusion of the offset term, however,
were largely the same.
A fully adjusted model was constructed including cova-
riates that are potentially associated with colorectal cancer
or polyunsaturated fatty acid intake as follows: years of
education (<12, 12–15, or 16 years), annual household
income (<$15,000, $15,000–$24,999, $25,000–$49,999,
or $50,000), smoking status (current, past, or never
smoker) at the time of diagnosis (for cases) or interview
(for controls), family history of colorectal cancer (having
had at least 1 first-degree relative with colorectal cancer or
not), NSAID use in the past 5 years (ever or never), hormone
replacement therapy use for at least 1 year in women, body



















<0.06 198 233 1.00 Referent 1.00 Referent
0.06–<0.11 194 237 0.79 0.61, 1.03 0.96 0.71, 1.31
0.11–<0.18 257 235 0.63 0.48, 0.83 0.75 0.54, 1.04




<0.01 319 257 1.00 Referent 1.00 Referent
0.01–<0.03 266 279 0.72 0.56, 0.92 0.89 0.67, 1.17
0.03–<0.05 177 192 0.65 0.50, 0.86 0.77 0.55, 1.06




<0.04 263 216 1.00 Referent 1.00 Referent
0.04–<0.07 259 250 0.76 0.59, 0.99 0.90 0.66, 1.22
0.07–<0.11 212 236 0.62 0.47, 0.82 0.75 0.55, 1.03
0.11 195 241 0.49 0.37, 0.66 0.58 0.41, 0.81
Ptrend <0.01 <0.01
x-6:x-3 PUFA ratio
<8.1 214 239 1.00 Referent 1.00 Referent
8.1–<9.2 259 238 1.17 0.90, 1.52 1.13 0.84, 1.53
9.2–<10.5 246 236 1.07 0.82, 1.39 1.00 0.74, 1.36




<90.3 171 235 1.00 Referent 1.00 Referent
90.3–<151.7 221 236 1.16 0.87, 1.53 1.05 0.76, 1.45
151.7–<254.7 227 236 1.27 0.96, 1.68 1.20 0.87, 1.65
254.7 310 236 1.75 1.34, 2.30 1.42 1.04, 1.95
Ptrend <0.01 0.02
Abbreviation: PUFA, polyunsaturated fatty acid.
a Adjusted for age (40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75–79 years), race,
sex, daily energy intake (<1,554.6, 1,554.6–<1,991.0, 1,991.0–<2,595.4, or 2,595.4 kcal/day),
and offset term.
b Additionally adjusted for years of education (<12, 12–15, 16 years), endoscopic screening
in the past 10 years (yes or no), red meat intake (<34.7, 34.7–<57.1, 57.1–<95.8, 95.8 g/day),
vitamin E intake (<6.6, 6.6–<9.2, 9.2–<12.4, 12.4 mg/day), and body mass index 1 year prior
(<25, 25–29.9, 30 kg/m2).
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endoscopic screening use in the past 10 years (yes or no),
and intakes of total fat, red meat, fruit and vegetables, and
vitamin E during the past year (quintiles based on the dis-
tribution among controls). Vitamin E was evaluated as a po-
tential covariate on the basis of findings from experimental
studies showing that long-chain x-3 ceased to exert its anti-
tumorigenic effects after concurrent addition of vitamin E
(7). Endoscopic screening use, years of education, body
mass index, and intakes of red meat and vitamin E resulted
in more than 10% changes in the beta coefficients for high-
est quartile of long-chain x-3 PUFA intake in relation to
distal large bowel cancer when covariates were removed;
therefore, they were included in the final multivariable
model in addition to age, sex, race, daily energy intake,
and an offset term.
Likelihood ratio tests comparing models with and without
multiplicative interaction terms were used to assess poten-
tial effect measure modification of the association between
PUFA intakes and distal large bowel cancer by race, NSAID
use, and self-reported body mass index. Subsite-specific ef-
fect estimates were modeled by using multinomial logistic
regression models. All statistical tests were 2 sided and had
an a level of 0.05. STATA, version 10.0, software (Stata-
Corp LP, College Station, Texas) was used for all statistical
analyses.
RESULTS
Among 929 cases and 943 controls with adequate dietary
information, the mean age was 62 years and 64 years, re-
spectively (Table 1). Compared with controls, cases were
more likely to be African Americans and less likely to take
NSAIDs and to receive endoscopic screening. Cases also
tended to be overweight or obese and had higher intakes
of polyunsaturated fat, total fat, and total energy, whereas
intakes of fruit and vegetables and long-chain x-3 PUFAs
were lower in cases compared with controls. Interestingly,
cases were more physically active than controls, but the
positive association disappeared after the minimal adjust-
ment for age, sex, and race (data not shown).
Long-chain x-3 PUFA intake was inversely related to dis-
tal large bowel cancer in a dose-response manner (Ptrend <
0.01) (Table 2). After adjustment for potential confounding
variables, the inverse association remained significant for the
highest quartile of long-chain x-3 fatty acid intake. The mul-
tivariable odds ratios were 0.96 (95% confidence interval
(CI): 0.71, 1.31) for the second quartile, 0.75 (95%
CI: 0.54, 1.04) for the third quartile, and 0.61 (95% CI:
0.44, 0.86) for the fourth quartile in comparison with the
lowest quartile, respectively. Further adjustment for vitamin
D, which is rare in the diet but is most abundantly found in
fatty fish as is long-chain x-3 PUFA (27), did not change the
estimated association between long-chain x-3 PUFA and dis-
tal large bowel cancer. We also analyzed the data using the
residual method for energy adjustment, but the estimates
remained largely unchanged (data not shown). Intakes of in-
dividual long-chain x-3 PUFAs, eicosapentaenoic acid, and
docosahexaenoic acid were also similarly inversely associ-
ated with distal large bowel cancer risk in a dose-dependent
manner (Ptrend< 0.01), whereas the ratio ofx-6 to long-chain
x-3 PUFA intake was associated with increased risk of distal
large bowel cancer (for the highest vs. the lowest quartile: the
multivariable odds ratio (OR) ¼ 1.42 (95% CI: 1.04, 1.95)).
On the other hand, intakes of total PUFAs, total x-6 PUFAs,
and short-chain x-3 PUFAs were not related to distal large
bowel cancer risk.
When we stratified by race, the inverse association be-
tween higher intake of long-chain x-3 PUFA and distal large
bowel cancer risk was limited to whites (Pinteraction ¼ 0.02)
(Table 3). Among African Americans, the intake of long-
chain x-3 PUFAs was positively associated with distal large
bowel cancer (for the highest vs. the lowest quartile: OR ¼
1.79 (95% CI: 0.85, 3.77)), although the trend was not sig-
nificant (Ptrend ¼ 0.49). Further adjustment for consumption
of saturated fatty acid and proportion of fried fish out of total
fish intake did not reverse the inverse association in African
Americans (data not shown). We also evaluated NSAID use
and obesity (body mass index, 30 kg/m2) as potential ef-
fect modifiers but found similar inverse associations across
the strata. There was no evidence of interaction with race,
NSAID use, or obesity for other types of PUFAs (data not
shown).
The relations with PUFAs did not vary by anatomic loca-
tion of tumor (Table 4). Increased consumption of long-chain
x-3 PUFAs was inversely related to reduced risk of sigmoid,
rectosigmoid, and rectal cancer in a dose-dependent manner
(all Ptrend < 0.05). The positive association with the ratio of
x-6 to long-chain x-3 PUFAs was also similarly observed for
all subtypes of distal large bowel cancer (for the highest vs.
the lowest quartile: multivariable ORs ¼ 1.39 (95% CI: 0.95,
2.03) for sigmoid cancer, 1.75 (95% CI: 0.95, 3.22) for rec-
tosigmoid cancer, and 1.34 (95% CI: 0.89, 2.02) for rectal
cancer, respectively).
DISCUSSION
In this population-based case-control study, we assessed
the relation between different PUFA intakes and the risk
of distal large bowel cancer. We observed a reduced risk
of distal large bowel cancer in relation to higher intake of
long-chain x-3 PUFAs and individual eicosapentaenoic acid
and docosahexaenoic acid. We also observed a significantly
increased risk of distal large bowel cancer with a high ratio
of x-6 to long-chain x-3 PUFAs. The associations were
limited to whites and not observed among African Ameri-
cans. However, there was no evidence of effect measure
modification by NSAID use, obesity, and tumor location.
Previous epidemiologic studies investigating the relation
between x-3 intake and colorectal cancer risk are limited
and inconsistent. A pooled analysis of 3 prospective studies
of the association between x-3 fatty acid intake and colo-
rectal cancer risk did not reach statistical significance (28),
and only 1 of 9 prospective studies included in an earlier
systematic review found a significant inverse relation (10).
More recently, marine x-3 PUFAs and intakes of total x-3
PUFAs and individual eicosapentaenoic acid and docosa-
hexaenoic acid were significantly associated with reduced
risk of colorectal cancer in a prospective cohort of men (12)
and in a Scottish case-control study (11). However, in other
974 Kim et al.
Am J Epidemiol 2010;171:969–979
studies, the inverse association was limited to men (29),
distal colon cancer (13), or nonadvanced colorectal cancer
(15), or no association was found (14).
Contrary to the inconsistent epidemiologic findings, there
is a wealth of experimental data demonstrating antiinflam-
matory and anticarcinogenic effects of x-3 PUFAs (7). Diets
high in x-3 PUFAs have been shown to be effective in re-
ducing tumor growth (1, 2) and metastases (4, 5) mainly
through effects on the cyclooxygenase pathway (7). High
intake of x-3 PUFAs can replace arachidonic acid in mem-
brane phospholipids (30) and compete for COX enzyme to
form eicosapentaenoic acid-derived eicosanoids in favor of
arachidonic acid-derived eicosanoids (7). Excess free arach-
idonic acid can perturb the homeostasis of normal eicosa-
noids (31), and arachidonic acid-derived eicosanoids such as
prostaglandin E2 and leukotriene B4 are precursors for
a number of key mediators of inflammation and cell pro-
liferation (6, 30). Moreover, x-3 PUFAs compete with x-6
PUFAs for desaturation and elongation enzymes, decreasing
the extent of conversion from linoleic acid to arachidonic acid
(7). Emerging evidence also suggests COX-independent
pathways of x-3 PUFAs in tumor suppression (7, 32): Tumor
formation was inhibited with x-3 PUFA-enriched diet in
athymic nude mice with and without cells injected with
COX-1 or COX-2 (32).
a-Linolenic acid is the major x-3 PUFA in Western diets;
its consumption is about 10 times higher than that of eico-
sapentaenoic acid or docosahexaenoic acid (26). Consistent
with previous findings (11, 33), our results did not show the
inverse association between a-linolenic acid and distal large
bowel cancer. It may not be surprising that the inverse asso-
ciation with colorectal cancer was limited to long-chain x-3
PUFAs. Although a-linolenic acid can also compete with x-6
PUFAs, its potency has been estimated to be approximately
one fifth that of eicosapentaenoic acid or docosahexaenoic
acid (7).Moreover, whereas a-linolenic acid can be converted
to eicosapentaenoic acid or docosahexaenoic acid in humans,
the extent of conversion is very inefficient: as low as 0.2% to
eicosapentaenoic acid and 0.05% to docosahexaenoic acid
(34). It has been shown that only eicosapentaenoic acid and
docosahexaenoic acid, but not a-linolenic acid, reduced tu-
morigenesis in ApcMin/þ mice (35).
In our study, the ratio of x-6 to long-chain x-3 PUFAs
was associated with an increased risk of distal large bowel
cancer, but intake of x-6 PUFAs per se was not related to
cancer risk. Increased serum levels of total x-6 PUFAs have
been positively associated with the risk of having colorectal
adenomas (36), but most previous studies did not find a pos-
itive association with high x-6 PUFA intake (11, 14, 15, 37).
Population-wide consumption of linoleic acid-rich foods is
high; a slight variation in linoleic acid intake may not affect
tissue arachidonic acid concentrations (7).
We found an unexpected positive association between
long-chain x-3 PUFA intake and distal large bowel cancer
risk in African Americans. It has been documented that
African Americans consume more fried foods than do
whites (38). Thus, we explored whether racial differences
in preferred preparation methods of fish may have influ-
enced the association between long-chain x-3 fatty acid
intake and distal large bowel cancer risk. In fact, the African
Americans in our study consumed fried fish more frequently
than whites did. However, the inverse association remained
Table 3. Association Between Quartiles of Long-Chain x-3 Polyunsaturated Fatty Acid Intake and Distal Large Bowel Cancer Risk According to































Whites 1.00 Referent 0.88 0.63, 1.22 0.69 0.49, 0.98 0.49 0.34, 0.71 <0.01
African Americans 1.00 Referent 1.86 0.86, 4 1.42 0.66, 3.05 1.79 0.85, 3.77 0.49
Pinteraction ¼ 0.02
NSAID use in the past 5 years
Yes 1.00 Referent 0.96 0.68, 1.35 0.79 0.55, 1.13 0.65 0.45, 0.93 0.01
No 1.00 Referent 1 0.51, 1.96 0.66 0.31, 1.35 0.51 0.26, 1 0.05
Pinteraction ¼ 0.86
Obesity
Body mass index 30 1.00 Referent 1.09 0.65, 1.86 0.72 0.42, 1.25 0.67 0.39, 1.17 0.17
Body mass index <30 1.00 Referent 0.9 0.62, 1.3 0.77 0.53, 1.14 0.59 0.4, 0.87 <0.01
Pinteraction ¼ 0.85
Abbreviation: NSAID, nonsteroidal antiinflammatory drug.
a Adjusted for age (40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75–79 years), race, sex, daily energy intake (<1,554.6, 1,554.6–
<1,991.0, 1,991.0–<2,595.4, 2,595.4 kcal/day), offset term, years of education (<12, 12–15, 16 years), endoscopic screening in the past 10
years (yes or no), red meat intake (<34.7, 34.7–<57.1, 57.1–<95.8, 95.8 g/day), vitamin E intake (<6.6, 6.6–<9.2, 9.2–<12.4, 12.4 mg/day),
and body mass index 1 year prior (<25, 25–29.9, 30 kg/m2).
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Table 4. Tumor-specific Odds Ratios and 95% Confidence Intervals According to Quartiles of Polyunsaturated

















Total PUFAs, g/day 0.95
<13.1 1.00 Referent 1.00 Referent 1.00 Referent
13.1–<18.1 0.92 0.59, 1.43 1.25 0.63, 2.50 1.50 0.93, 2.44
18.1–<24.4 1.05 0.62, 1.78 1.70 0.76, 3.81 1.06 0.59, 1.93
24.4 1.02 0.54, 1.91 0.89 0.33, 2.35 1.04 0.52, 2.09
Ptrend 0.86 0.82 0.82
Total x-6 PUFAs, g/day 0.81
<11.5 1.00 Referent 1.00 Referent 1.00 Referent
11.5–<16.3 0.84 0.54, 1.30 1.22 0.62, 2.41 1.43 0.88, 2.31
16.3–<22.0 1.01 0.60, 1.71 1.53 0.69, 3.43 0.97 0.53, 1.76
22.0 0.82 0.44, 1.55 0.75 0.28, 1.98 1.01 0.51, 2.03
Ptrend 0.70 0.56 0.79
Total x-3 PUFAs, g/day 0.64
<1.27 1.00 Referent 1.00 Referent 1.00 Referent
1.27–<1.72 1.16 0.77, 1.74 0.83 0.42, 1.64 1.40 0.72, 1.81
1.72–<2.31 0.90 0.56, 1.45 1.74 0.84, 3.59 1.25 0.74, 2.10
2.31 0.83 0.48, 1.43 1.03 0.45, 2.37 1.13 0.62, 2.04
Ptrend 0.37 0.72 0.68
Short-chain x-3 PUFAs, g/day 0.34
<1.16 1.00 Referent 1.00 Referent 1.00 Referent
1.16–<1.57 0.91 0.60, 1.38 0.84 0.43, 1.64 1.22 0.76, 1.96
1.57–<2.14 0.99 0.62, 1.58 1.39 0.68, 2.85 1.57 0.93, 2.64
2.14 0.87 0.50, 1.49 0.91 0.40, 2.09 1.39 0.76, 2.52
Ptrend 0.72 0.93 0.238
Long-chain x-3 PUFAs, g/day 0.84
<0.06 1.00 Referent 1.00 Referent 1.00 Referent
0.06–<0.11 0.88 0.61, 1.26 0.81 0.48, 1.37 1.17 0.78, 1.74
0.11–<0.18 0.68 0.46, 1.00 0.57 0.32, 1.02 0.97 0.64, 1.47
0.18 0.61 0.41, 0.92 0.55 0.31, 1.00 0.67 0.43, 1.05
Ptrend <0.01 0.03 0.05
x-6:x-3 PUFA ratio 0.18
<8.1 1.00 Referent 1.00 Referent 1.00 Referent
8.1–<9.2 1.16 0.80, 1.67 1.43 0.83, 2.46 1.00 0.68, 1.48
9.2–<10.5 0.99 0.68, 1.45 0.96 0.54, 1.71 1.02 0.69, 1.51
10.5 1.23 0.83, 1.83 1.35 0.75, 2.43 0.83 0.54, 1.28
Ptrend 0.48 0.66 0.49
x-6:long-chain x-3 PUFA ratio 0.72
<90.3 1.00 Referent 1.00 Referent 1.00 Referent
90.3–<151.7 1.09 0.74, 1.60 1.23 0.65, 2.35 0.95 0.62, 1.45
151.7–<254.7 1.06 0.71, 1.56 2.01 1.10, 3.68 1.10 0.72, 1.68
254.7 1.39 0.95, 2.03 1.75 0.95, 3.22 1.34 0.89, 2.02
Ptrend 0.10 0.03 0.09
Abbreviation: PUFA, polyunsaturated fatty acid.
a Wald test P value for heterogeneity of the beta coefficient for highest quartile across tumor location.
b Adjusted for age (40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75–79 years), race, sex, daily energy
intake (<1,554.6, 1,554.6–<1,991.0, 1,991.0–<2,595.4, 2,595.4 kcal/day), offset term, years of education (<12,
12–15,16 years), endoscopic screening in the past 10 years (yes or no), red meat intake (<34.7, 34.7–<57.1, 57.1–
<95.8,95.8 g/day), vitamin E intake (<6.6, 6.6–<9.2, 9.2–<12.4,12.4 mg/day), and body mass index 1 year prior
(<25, 25–29.9, 30 kg/m2).
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unchanged after further adjustment for the relative propor-
tion of fried fish out of total fish intake and intake of sat-
urated fatty acids. Moreover, higher intakes of the 3 major
food items for fish consumption, such as canned tuna, fish
sticks/fried fish, and nonfried fish and seafood, were all
inversely associated with distal large bowel cancer risk in
whites. On the other hand, x-3 PUFA intake assessed
from the questionnaire may represent the bioavailability
of specific fatty acids more poorly in African Americans
compared with whites. In a small study conducted in the
same catchment area as this study, correlations of food
frequency questionnaire estimates of both eicosapenta-
enoic acid and docosahexaenoic acid with concentrations
in erythrocytes and adipose tissue were substantially lower
in African Americans than in Caucasians (39). Finally,
such statistical heterogeneity of the association may indi-
cate different carcinogenic processes in African Americans
and whites. Although we did not find studies of African
Americans to compare our findings, we previously ob-
served inverse association with NSAIDs only among
whites (40). Given that 2 potentially chemopreventive
agents sharing COX-2 and inflammation pathways were
inversely associated with colorectal cancer risk only
among whites, it is possible that the inflammation path-
ways may be less important in colorectal carcinogenesis
among African Americans. However, caution is required in
such interpretation because the findings may have been due
to chance.
Limitations of the current study include the retrospective
nature of data collection. Although our food frequency ques-
tionnaire was designed to query habitual diet before the di-
agnosis of disease, prediagnosis symptoms may have altered
the diet of cases, or diagnosis of cancer itself may have
influenced past diet on recall (22). However, it is unlikely
that either prediagnosis symptoms or diagnosis of cancer
would lead cases to avoid fish consumption, which is the
major source of long-chain x-3 PUFAs (26).
Intake of polyunsaturated fatty acids in our study was
estimated from a single measure of usual dietary intake de-
rived from a food frequency questionnaire and, thus, mea-
surement errors inherent in such dietary assessment apply to
our study. Particularly, fat is often used in food preparation
and hard to recognize and quantify from the food frequency
questionnaire, and it may be underreported in overweight or
obese individuals because of social implications (41). How-
ever, among the different types of fatty acids, x-3 PUFAs
appear to be least subject to these issues as shown by higher
correlation between food frequency questionnaire estimates
and biomarker as high as 0.8 for docosahexaenoic acid com-
pared with 0.3 for monounsaturated fats (41).
Long-chain x-3 PUFA supplements contain high amounts
of eicosapentaenoic acid and docosahexaenoic acid (42). In
our study, 21 (1.1%) and 118 (6.3%) participants reported
taking cod liver oil or fish oil supplements more than once
per week, respectively. Excluding the supplement users
from the analyses did not change the association between
long-chain x-3 PUFA and distal large bowel cancer. Simi-
larly, the results remained unchanged when the supplement
users were added to the highest quartile of dietary intakes of
long-chain x-3 PUFA.
In this study, we examined 11 groupings of polyunsatu-
rated fatty acids that are categorized on the basis of their
biochemical and nutritional characteristics. This may raise
concern over multiple comparisons. However, we did not
adjust for multiple testing, because Bonferroni correction
and other traditional statistical procedures that assume
independence of hypotheses do not protect against type 1
error associated with multiple testing of such highly cor-
related hypotheses (43). Instead, we interpreted individual
associations in the context of epidemiologic and experi-
mental studies as well as our own data, as previously
recommended (44, 45). Residual confounding remains
a potential limitation to our study. Intake of long-chain
x-3 PUFAs may represent a generally healthy diet and
lifestyle. In fact, endoscopic screening, obesity, and in-
takes of meat and vitamin E were important confounders
in our analyses. However, adjustment for these variables
still did not fully diminish the association with long-chain
x-3 PUFA intake. The possibility of selection bias should
also be considered. The participation rate among controls
in our study was 56%, which does not appear to be unusual
in contemporary population-based case-control studies
(46). Participating individuals may represent groups of
higher socioeconomic status and healthier lifestyles than
the target population (47). However, in our study, the
association between long-chain x-3 PUFA and distal large
bowel cancer was relatively strong, with an estimated odds
ratio of 0.61 for the comparison of the highest versus
the lowest quartiles, and therefore, it is unlikely that this
finding is accounted for entirely by selection bias.
In conclusion, the results of this study support the hypoth-
esis that increasing consumption of long-chain x-3 PUFAs
may be beneficial in preventing distal large bowel cancer.
Whether the possible benefit from this dietary modification
varies by race warrants further evaluation.
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